SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001654954-19-011103
Filing Date
2019-09-25
Accepted
2019-09-25 17:25:31
Documents
10
Period of Report
2019-09-25
Items
Item 7.01: Regulation FD Disclosure
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT azrx8k_20190925.htm 8-K 35147
2 PRESS RELEASE ex99-1.htm EX-99.1 22438
3 CORPORATE PRESENTATION ex99-2.htm EX-99.2 8539
4 IMAGE ex99-2000.jpg GRAPHIC 24178
5 IMAGE ex99-20002.jpg GRAPHIC 34153
6 IMAGE ex99-20007.jpg GRAPHIC 62545
7 IMAGE ex99-2002.jpg GRAPHIC 54329
8 IMAGE ex99-2003.jpg GRAPHIC 42400
9 IMAGE ex99-2004.jpg GRAPHIC 43869
10 IMAGE ex99-2005.jpg GRAPHIC 50052
  Complete submission text file 0001654954-19-011103.txt   497248
Mailing Address 760 PARKSIDE AVENUE SUITE 304 BROOKLYN NY 11226
Business Address 760 PARKSIDE AVENUE SUITE 304 BROOKLYN NY 11226 646-699-7855
AzurRx BioPharma, Inc. (Filer) CIK: 0001604191 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE
Type: 8-K | Act: 34 | File No.: 001-37853 | Film No.: 191114995
SIC: 2834 Pharmaceutical Preparations